Meiji Seika Pharma’s Nacubactam to Be Featured in 10 Presentations at ESCMID Global 2026 — Including Phase III Integral-2 Results
15.4.2026 08:00:00 CEST | Business Wire | Press Release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that at ESCMID Global 2026, to be held from 17 to 21 April 2026, it will present a total of ten studies on its novel β-lactamase inhibitor nacubactam (development code: OP0595), for which a manufacturing and marketing authorisation application is under review in Japan. The presentations include results from Integral-2, an international, multicentre Phase III clinical trial in patients with infections due to carbapenem-resistant Enterobacterales (CRE).
Currently, carbapenem-resistant bacteria pose a global threat because carbapenems are considered last-resort agents for severe infections. The development and approval of effective agents against multidrug-resistant Gram-negative bacteria, including CRE, are urgently needed (WHO Bacterial Priority Pathogens List, 2024). In December 2025, Meiji Seika Pharma submitted an application for manufacturing and marketing approval of nacubactam in Japan and remains committed to contributing to global efforts against AMR—the “silent pandemic.”
The planned presentations are as follows:
- Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam vs best available therapy in adults with cUTI/AP, HABP/VABP, cIAI due to carbapenem resistant Enterobacterales: Integral-2, single-blind, randomised phase III trial — Oral presentation (O0107); Clinical
- Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of Integral-1 study — Poster (P2876); Poster Walkthrough (R0058); Clinical
- Outcomes of cefepime/nacubactam and aztreonam/nacubactam in cUTI/AP patients with ESBL-producing bacteria enrolled into prospective phase III randomised clinical study (Integral-1) — Poster (P2864); Clinical
- Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam compared with imipenem/cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis: Integral-1, a double-blind, randomised phase III trial — Poster (P2857); Clinical
- The in vitro activity of aztreonam/nacubactam and cefepime/nacubactam against molecularly characterised Enterobacterales isolates including those with ceftazidime-avibactam and aztreonam/avibactam resistance mechanisms collected globally from 2021–2023 — Top Rated Poster (P1622); Non-clinical
- Activity of the novel combination therapy cefepime/nacubactam against 17,220 clinical isolates of Enterobacterales collected worldwide during 2021–2024 — Poster (P1197); Non-clinical
- In vitro activity of nacubactam against broad-spectrum β-lactamases — Poster (P2659); Non-clinical
- Probability of target attainment of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant Enterobacterales infections — Poster (P2742); PK/PD
- Population pharmacokinetic analysis of nacubactam, cefepime, and aztreonam and exposure–response analysis of efficacy results from phase III clinical trials — Poster (P2743); PK/PD
- Determination of the nonclinical PK/PD target value for nacubactam in a mouse thigh infection model using carbapenem-resistant Enterobacterales under co-administration of cefepime or aztreonam — Poster (P2744); PK/PD
Following congress selection, O0107 was chosen for an Oral Presentation, P2876 for the Poster Walkthrough session, and P1622 as a Top Rated Poster (top 2%).
About nacubactam (development code: OP0595)
Nacubactam (development code: OP0595) is a novel β-lactamase inhibitor discovered by Meiji Seika Pharma. In combination with existing β-lactam antibiotics such as cefepime or aztreonam, nacubactam is expected to be effective against carbapenem-resistant Enterobacterales (CRE), including carbapenemase-producing strains. In addition, nacubactam inhibits penicillin-binding protein 2 (PBP2), an enzyme involved in the biosynthesis of peptidoglycan in the bacterial cell wall, thereby conferring a property that distinguishes it from other β-lactamase inhibitors.
In the Integral-1 trial, for the primary endpoint of composite clinical and microbiological response at seven days after the end of treatment, superiority of cefepime/nacubactam over imipenem/cilastatin and non-inferiority of aztreonam/nacubactam to the same comparator were demonstrated. With respect to safety, no significant safety concerns were observed (press release dated 14 March 2025).
In the Integral-2 trial, for the primary endpoint of overall composite response at seven days after the end of treatment across all enrolled indications, high efficacy of both cefepime/nacubactam and aztreonam/nacubactam was confirmed compared with best available therapy. With respect to safety, no significant safety concerns were observed.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260414424880/en/
Contacts
For further information:
Meiji Seika Pharma Co., Ltd.
Hayato Okade
Project Manager, Nacubactam
pr-pharma@meiji.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Scoot, Qatar, and Ryanair Top Cirium Global Airline Emissions Rankings in 202515.4.2026 11:00:00 CEST | Press Release
Singapore-based Scoot has been named the world’s most emissions-efficient airline in Cirium’s 2025 EmeraldSky Annual Review, taking the top position from last year’s leader, Wizz Air. Qatar Airways, Ryanair, and Turkish Airlines were each recognized as the top three most efficient global airlines, ranked by available seat kilometres (ASK). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415951838/en/ EmeraldSky Gold 2025: Awarded to the world’s top five most emissions-efficient airlines, based on CO₂ per available seat kilometre (ASK). Cirium’s industry leading ranking is based on CO₂ per available ASK across the world’s 100 largest airlines. The methodology is independently assured by PwC to ISAE 3000. It groups airlines into Gold, Silver and Bronze tiers based on global performance, which covers the top 15 airlines as well as key regional and route performers. “Airline emissions performance comes down to decisions airlin
Scoot, Qatar, and Ryanair Top Cirium Global Airline Emissions Rankings in 202515.4.2026 11:00:00 CEST | Press Release
Singapore-based Scoot has been named the world’s most emissions-efficient airline in Cirium’s 2025 EmeraldSky Annual Review, taking the top position from last year’s leader, Wizz Air. Qatar Airways, Ryanair, and Turkish Airlines were each recognized as the top three most efficient global airlines, ranked by available seat kilometres (ASK). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415951838/en/ EmeraldSky Gold 2025: Awarded to the world’s top five most emissions-efficient airlines, based on CO₂ per available seat kilometre (ASK). Cirium’s industry leading ranking is based on CO₂ per available ASK across the world’s 100 largest airlines. The methodology is independently assured by PwC to ISAE 3000. It groups airlines into Gold, Silver and Bronze tiers based on global performance, which covers the top 15 airlines as well as key regional and route performers. “Airline emissions performance comes down to decisions airlin
SOLUM Receives Two Red Dot Product Design Awards for Shelf-Edge and In-Store Communication Solutions15.4.2026 10:20:00 CEST | Press Release
SOLUM (KOSPI: 248070) has received the Red Dot Award: Product Design for Newton Core+ and Newton E-Paper 32”, with both products recognised for addressing core retail requirements across function, design quality, ease of use, and responsibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415714608/en/ Red Dot Product Design Awards 2026 highlight Newton Core+ and Newton E-Paper 32” (Image: SOLUM) As retailers place greater emphasis on solutions that support store presentation, operational usability, and long-term reliability, the awards highlight two products developed around those priorities. Newton Core+ and Newton E-Paper 32” reflect a retail technology approach shaped by the practical demands of the store environment, where visual consistency, day-to-day usability, and dependable performance all matter. Newton Core+: Premium Shelf-Edge Design Must Also Withstand Daily Retail Use For Newton Core+, the recognition hi
SOLUM Receives Two Red Dot Product Design Awards for Shelf-Edge and In-Store Communication Solutions15.4.2026 10:20:00 CEST | Press Release
SOLUM (KOSPI: 248070) has received the Red Dot Award: Product Design for Newton Core+ and Newton E-Paper 32”, with both products recognised for addressing core retail requirements across function, design quality, ease of use, and responsibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415714608/en/ Red Dot Product Design Awards 2026 highlight Newton Core+ and Newton E-Paper 32” (Image: SOLUM) As retailers place greater emphasis on solutions that support store presentation, operational usability, and long-term reliability, the awards highlight two products developed around those priorities. Newton Core+ and Newton E-Paper 32” reflect a retail technology approach shaped by the practical demands of the store environment, where visual consistency, day-to-day usability, and dependable performance all matter. Newton Core+: Premium Shelf-Edge Design Must Also Withstand Daily Retail Use For Newton Core+, the recognition hi
Navan Selected by Opella to Streamline Global Travel and Expense15.4.2026 09:01:00 CEST | Press Release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense management platform, today announced it has been selected by Opella to manage its global travel and expense programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415188706/en/ Self-care company aims to simplify employee T&E experience and targets cost savings with AI-powered platform “Navan provides our teams with an easy-to-use tool that removes the complexity from business travel and expense, improving our employee experience and giving us the real-time visibility required to effectively manage costs,” said Vincent Cotard, VP Global Head Real Estate and Workplace Experience at Opella. "Our employees will now have the easiest way to book travel and manage their expenses as we look to automate processes across the business.” Following Opella’s carve-out from Sanofi, the self-care company sought an AI-powered partner to provide employees with an ea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom